In September the European Medicines Agencys EMA Committee for Medicinal Products for Human Use CHMP adopted a positive opinion recommending marketing authorization to expand the indication for VOXZOGO for injection to treat children with achondroplasia aged 4 months and older whose epiphyses are not closed